All In Biotech

Drug Trial Radar · NCT05776927

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

A Double-dummy, Double-blind, Randomized, Active Controlled, Two-way Cross-over Study With 12 Week Treatment Duration Period, to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

188

Planned (sponsor's estimate)

Start

Aug 4, 2026

Primary completion

Dec 30, 2028

Study completion Jan 30, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of indacaterol acetate / glycopyrronium bromide / mometasone furoate (QVM149) compared to salmeterol xinafoate / fluticasone propionate in children from 12 to less than 18 years of age with asthma with pre-bronchodilator FEV1 ≥ 50 % of the predicted normal value for the participant.

Conditions

  • Asthma

Interventions

  • QVM149Drug

    QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg once daily delivered via Breezhaler®

  • Salmeterol Xinafoate / Fluticasone PropionateDrug

    Salmeterol xinafoate 50 μg / fluticasone propionate 500 μg twice daily delivered via Girohaler®

  • Placebo to QVM149Drug

    Placebo to QVM149 150/50/160 µg once daily delivered via Breezhaler®

  • Placebo to salmeterol xinafoate / fluticasone propionateDrug

    Placebo to salmeterol xinafoate/fluticasone propionate 50/500 μg twice daily delivered via Girohaler®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Trough FEV1Time frame: Baseline, Week 12 of each treatment period.

Locations

27 sites in 10 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Novartis Investigative Site

    Strasbourg, France · Recruiting

  • Novartis Investigative Site

    Bielefeld, Germany · Recruiting

  • Novartis Investigative Site

    Wesel, North Rhine-Westphalia, Germany · Recruiting

  • Novartis Investigative Site

    Szeged, Hungary · Recruiting

  • Novartis Investigative Site

    Bialystok, Poland · Recruiting

  • Novartis Investigative Site

    Krakow, Poland · Recruiting

  • Novartis Investigative Site

    Lublin, Poland · Recruiting

  • Novartis Investigative Site

    Piaseczno, Poland · Recruiting

  • Novartis Investigative Site

    Torun, Poland · Recruiting

  • Novartis Investigative Site

    Tarnów, Poland, Poland · Recruiting

  • Novartis Investigative Site

    Bucharest, Romania · Recruiting

  • Novartis Investigative Site

    Banská Bystrica, Slovakia · Recruiting

  • Novartis Investigative Site

    Bratislava, Slovakia · Recruiting

  • Novartis Investigative Site

    Košice, Slovakia · Recruiting

  • Novartis Investigative Site

    Bratislava, Mestska Cast Ruzinov, Slovakia · Recruiting

  • Novartis Investigative Site

    Cape Town, South Africa · Recruiting

  • Novartis Investigative Site

    Pretoria, South Africa · Recruiting

  • Novartis Investigative Site

    East London, Eastern Cape, South Africa · Recruiting

  • Novartis Investigative Site

    Germiston, Gauteng, South Africa · Recruiting

  • Novartis Investigative Site

    Krugersdorp, Gauteng, South Africa · Recruiting

  • Novartis Investigative Site

    Lenasia, Gauteng, South Africa · Recruiting

  • Novartis Investigative Site

    Paarl, Western Cape, South Africa · Recruiting

  • Novartis Investigative Site

    Seville, Spain · Recruiting

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, Spain · Recruiting

  • Novartis Investigative Site

    Sabadell, Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Kaohsiung City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.